ReviewDrug safety2019
Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Rasmus M Christensen et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
14 papers cite it
this paperpooled ittrialcites it
ReviewDrug safety2019
Rasmus M Christensen et al.PubMed ↗Publisher ↗
No numbers read from the abstract.